Hyperpigmentation Disorders Treatment Market Highlights

Hyperpigmentation disorder are harmless skin condition caused by darkened skin patches. Rising demand for outpatient dermabrasion procedures, increasing adoption of lasers and growing cosmetics expenditure are expected to drive the growth of the market. Additionally, rising RD spending followed aggressive strategies by the key market players is generating awareness for the disease boosting the market to grow. According to the American Society of Plastic Surgeons, the number of dermabrasion cosmetic procedures have increased from 42,218 in 2000 to 88,182 in 2016 with a 109% increase during the estimated period.

The Hyperpigmentation Disorders Treatment Market is expected to reach USD 7.6 Billion by 2030 at 7.60% CAGR during the forecast period 2022-2030.

However, factors such as the lack of adequate reimbursement policy and high costs procedures is estimated to restraint the market.

Regional Analysis

The Asia-Pacific are likely to dominate the global hyperpigmentation disorders treatment market.  Rising awareness of hyperpigmentation disorders, presence of rapidly developing healthcare technology, huge patient population, and high healthcare expenditure are some of the factors driving the market. The Americas stood second in the global hyperpigmentation disorders treatment market owing to government funding and support for healthcare sector. Moreover, presence of developed economies like US and Canada provides suitable backgrounds for the market growth. Europe is expected to be the third largest hyperpigmentation disorders treatment market trends. Following the Europe, the Middle East Africa is expected to account for the least share of the global hyperpigmentation disorders treatment market.

Hyperpigmentation Disorders Treatment Market Players

The global hyperpigmentation disorders treatment market players Allergan, Inc., Bayer AG, EpiPharm AG, Episciences, Inc., Galderma laboratories (Nestle Skin Health S.A), Obagi Cosmeceuticals LLC, Pierre Fabre, RXi Pharmaceuticals Corporation, SkinCeuticals International, and Vivier Pharma.

Segmentation

The global hyperpigmentation disorders treatment market insights has been segmented based on treatment type, disease indication, end-user, and region.

Based on treatment type, the market has been classified as topical drugs, chemical peels, microdermabrasion devices, laser therapy, phototherapy, and others. The market, by disease indication, has been segmented into melasma, solar lentigines, post-inflammatory hyperpigmentation, and others. based on end-user, the market has been segmented into hospitals, aesthetic clinics dermatology centres, and others. The topical drugs segment is expected to hold the largest market share of the hyperpigmentation disorders treatment market, by treatment type, during the forecast period. Also, by disease indication melasma segment register the considerable growth in comparison to other disease indication.

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.

Contact us:

Market Research Future (part of Wantstats Research and Media Private Limited),

99 Hudson Street, 5Th Floor,

New York, New York 10013

United States of America

+1 628 258 0071

Email: [email protected]